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I. INTRODUCTION
It started off innocently enough. As you walked around the corner you failed to see 
the forklift, and the driver failed to see you. You could feel the pain in your shoulder before 
you even hit the floor. The surgeon said it would be an easy recovery. For two months, 
you drove an hour to the city once a week, either to see the surgeon or for physical therapy. 
Those two months you used sick leave; actually, all of your sick leave and a few unpaid 
days since you had not been working long enough to qualify for the Family Medical Leave 
Act (“FMLA”).1 When you missed your second appointment, the surgeon dismissed you
for failure to follow-up. After some pleading, you convinced your doctor, the only doctor 
in your town of fifteen hundred, to write prescriptions for your pain medicine.  
That was eight months ago. Your doctor, a kindly, older man with a friendly bedside 
manner and a candy dish in the lobby, was not as strict as the surgeon; he did not have the 
time or training to monitor for the signs of addiction or misuse. He was not aware, and you 
did not volunteer, that you sometimes buy extra pills from friends because you sometimes 
need more than you did before. Once, he refused to write your prescription. You panicked 
and visited your mom. Seeing mom always helps. And you knew she still had your dad’s 
pain medicine from when he had cancer. After stealing pills from a dead parent to treat 
pain from shoulder surgery, pain that should no longer be there, you realize you need to 
make a change. You talk to your doctor. You tell him about the extra pills. You tell him 
that you want to stop. He tells you about treatments available, about therapy and 
medications that are very effective when combined. Then the excitement turns to concern. 
Doctors need a special license to prescribe those medications and no one in town has it. 
He says that he can set up an appointment for you with a doctor in the city. You will have 
to take off more time from work. 
Despite the current headlines, the Opioid Epidemic is a recurring theme in human 
history. And Opioid Use Disorder (“OUD”), while a relatively new diagnosis, is also an 
old problem.2 Since humankind first discovered the opium poppy,3 and especially since a 
 1. The Family Medical Leave Act provides employees with job-protected unpaid leave for qualified medical 
and family reasons. There are requirements to qualify, which include minimum hours worked and time employed. 
See FMLA Frequently Asked Questions, U.S. DEP’T. OF LABOR,  https://www.dol.gov/agencies/whd/fmla (last 
visited Jan. 24, 2021). 
 2. Sankar Banyopadhyay, An 8,000-year History of Use and Abuse of Opium and Opioids: How That 
Matters for a Successful Control of the Epidemic?, NEUROLOGY (Apr. 16, 2019), 
https://n.neurology.org/content/92/15_Supplement/P4.9-055.  
 3. 21 U.S.C. § 802(19). Papaver somniferum, commonly called the opium poppy, is a flowering plant. It is 
the source of opium as well as poppy seeds for muffins. Breadseed or Opium Poppy, Papaver somniferum,
WISCONSIN MASTER GARDENER (June 12, 2017), 
https://mastergardener.extension.wisc.edu/files/2017/06/Papaver_somniferum.pdf.  
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pharmacist discovered morphine,4 humans have had a love-hate relationship with this 
drug. Human history, dating back to the dark ages, reveals attempts to alleviate pain and 
ease suffering.5 Following the Civil War and the discovery of morphine,6 it became very 
fashionable to treat even the mildest of pain with the strongest pain medicine ever 
discovered.7 America’s first opioid epidemic was in the late 1800s.8 Primarily upper-
middle-class white women, with the financial means to visit a physician, were 
overprescribed potent painkillers for everything from diarrhea to a toothache and from a 
cough to menstrual cramps.9
Telemedicine could provide another treatment option for the current opioid crisis. 
Though telehealth has been defined in broad terms encompassing almost any health-
related activity combined with technology, telemedicine is the provision of typically in-
person care via real-time videoconferencing equipment.10 As technology has improved, 
telemedicine has advanced to include patient monitoring functions, diagnostic tests, and 
access to specialists located hundreds of miles from the patient.11 The latter development, 
connecting patients with specialists that are otherwise out of reach, would be especially 
useful for the current opioid epidemic. 
Medication-assisted therapy (“MAT”) is the “use of medications, in combination 
with counseling and behavioral therapies, to provide a ‘whole patient’ approach to 
treatment of OUD.”12 However, due to regulations designed in part to help limit the illicit 
distribution of controlled substances and in part to punish those unfortunate enough to 
develop OUD, medication-assisted therapy has several artificial roadblocks. While the 
federal government has placed no limits on the number of patients a physician can treat 
 4. Gillian R. Hamilton & Thomas F. Baskett, In the Arms of Morpheus: the Development of Morphine for 
Postoperative Pain Relief, 47 CAN. J. ANESTHESIA 367, 369 (2000). 
 5. Michael J. Brownstein, A brief history of opiates, opioid peptides, and opioid receptors, 90 PROC. NAT’L.
ACAD. SCI. 5391 (1993). 
 6. Gillian R. Hamilton & Thomas F. Baskett, supra note 4, at 368.  
 7. Ramtin Arablouei & Rund Abdelfatah, A History of Opioids in America, NPR (Apr. 4, 2019), 
https://www.npr.org/2019/04/04/709767408/a-history-of-opioids-in-america. 
8. Id.
 9. Mark R. Jones, et al., A Brief History of the Opioid Epidemic and Strategies for Pain Medicine, 7 PAIN 
& THERAPY 13, 15 (2018); See David Herzberg, Entitled to Addiction? Pharmaceuticals, Race, and America’s 
First Drug War, 91 BULLETIN INST. HIST. MED. 586 (2017). Mr. Herzberg’s article notes the preferential status 
federal drug law has created for white men and women, but especially upper-middle class white women, when 
accessing healthcare and obtaining controlled substances. This disparity was explored in recent research 
estimating that an additional 14,000 opioid-related deaths would have occurred if black Americans were 
prescribed opioids at a rate equal to white Americans. See Monica Alexander, et al., Trends in Black and White 
Opioid Mortality in the United States, 1979-2015, 29 EPIDEMIOLOGY 707, 707–08 (2018); Austin Frakt & Toni 
Monkovic, A ‘Rare Case Where Racial Biases’ Protected African-Americans, N.Y. TIMES (Nov. 25, 2019),
https://www.nytimes.com/2019/11/25/upshot/opioid-epidemic-blacks.html; see also Arablouei & Abdelfatah, 
supra note 7. 
 10. Eric Wicklund, Is There a Difference between Telemedicine and Telehealth?, MHEALTH INTELLIGENCE 
(June 3, 2016), https://mhealthintelligence.com/features/is-there-a-difference-between-telemedicine-and-
telehealth. 
 11. Telehealth, Telemedicine and Telecare: What’s What?, FED. COMMC’NS COMM’N,
https://www.fcc.gov/general/telehealth-telemedicine-and-telecare-whats-what [hereinafter FCC]. 
 12. Chapter 38 - Internet Eligible Controlled Substance Provider Designation., INDIAN HEALTH SERV.,
https://www.ihs.gov/ihm/pc/part-3/chapter-38-internet-eligible-controlled-substance-provider-designation/. 
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with opioids,13 there is a limit on the number of patients with OUD a physician can help.14
Providers who wish to provide MAT must meet certain educational requirements and 
enroll in a special program with the Drug Enforcement Agency (“DEA”).15 Until recently, 
enrollment was limited to physicians, excluding nurse practitioners and physician 
assistants who make up the majority of providers in rural settings.16 The use of 
telemedicine to deliver MAT therapy would greatly expand access to this effective OUD 
treatment. The combination of telemedicine and MAT would especially benefit rural 
patients, where opioid addiction is prevalent and access to addiction treatment 
practitioners is limited.17
This comment begins by explaining the history of opioid use and abuse, the 
development of telemedicine, and how current controlled substance legislation prevents 
the use of telemedicine to address the opioid crisis. Part II covers the history and 
development of opioids, briefly explaining the physiology of pain and opioids in the body; 
it explores the physiology and psychology of opioid addiction and the paradigm shift to 
opioid use disorder as a way of viewing addiction as a chronic disease state that can be 
treated.  
Part III explores legislation designed to regulate the use and distribution of 
controlled substances. The Harrison Narcotics Act, passed in 1914, was the federal 
government’s first attempt at controlled substance regulation. The Controlled Substance 
Act (“CSA”), passed in 1970, serves a broad purpose of regulating the manufacture, 
importation, and distribution of controlled substances.18 It also regulates healthcare and 
medical practices involving controlled substances, including restrictions on where and 
how addiction treatment can be provided.19 The Drug Addiction Treatment Act of 2000 
amended the CSA to allow qualified physicians to prescribe narcotics for the purpose of 
treating OUD on an out-patient basis. The Ryan Haight Online Pharmacy Consumer 
Protection Act of 2008 (“Ryan Haight Act”), an amendment to the CSA, places restrictions 
on prescribing controlled substances via the internet. 
Part IV examines case law and other evidence to demonstrate that the Ryan Haight 
Act was unnecessary and ineffective legislation. Part IV then provides a prescription for 
legislative and regulatory solutions to allow the adoption of telemedicine to address the 
opioid crisis and shortage of substance abuse practitioners. Using telemedicine to provide 
medication-assisted therapy would provide a dramatic increase in treatment options for 
those diagnosed with OUD. Part IV advocates for an update to the definition of 
13. See generally Akshara Menon, et al., Prescription Drug Time and Dosage Limit Laws, PUB. HEALTH 
LAW (Mar. 5, 2015), http://www.cdc.gov/phlp/docs/menu_prescriptionlimits.pdf (summarizing and referencing 
laws regulating controlled substance prescriptions.). 
 14. 21 U.S.C. § 823(g)(2)(B)(iii)(I). 
 15. Become a Buprenorphine Waivered Practitioner, SAMHSA (last updated Sept. 1, 2020 ),  
https://www.samhsa.gov/medication-assisted-treatment/become-buprenorphine-waivered-practitioner. 
 16. Comprehensive Addiction and Recovery Act of 2016, Pub. L. No. 114-198,  130 Stat. 721–23 amended 
the Controlled Substances Act to allow qualified nurse practitioners and physician assistants to provide OUD 
treatment to patients in an office-based setting. 
    17.   Drug Overdose in Rural America, CDC, https://www.cdc.gov/ruralhealth/drug-overdose/ (last visited 
Dec. 20, 2020).
 18. 21 U.S.C. § 801 
19. See 21 U.S.C. §§ 353(b), 802(21), and 829(b). 
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telemedicine to reflect advances in technology and changes in practice. It suggests that 
Congress remove the in-person medical examination requirement found in the Ryan 
Haight Act. Finally, it encourages Congress to update DATA 2000 to allow all physicians 
to prescribe medications for OUD treatment. 
II. OPIOIDS AND TELEMEDICINE—THE PAST AND FUTURE OF MEDICINE
A. Opioids 
i. Opium – The Pied Piper20 of Medicine 
“For such as cannot sleep, or are grievously pained, and upon whom being cut, or 
cauterized they wish to make a not-feeling pain.” - Dioscorides21
Humans for millennia have sought out relief from pain and cures from illness from 
their surroundings.22 Due to their abundance and ease of use, plants have been the 
dominant source of medicinal substances.23 Early human writings evidence attempts at 
procuring relief using concoctions derived from plants.24 Clay tablets found in 
Mesopotamia record the use of opium by the Sumerians almost 5400 years ago; they 
named it Hul Gil, the joy plant.25 This record is one of the earliest documenting the 
cultivation and use of opium poppies.26 From Mesopotamia, opium spread along historic 
trade routes to the rest of the ancient world.27
Originally, opium was only consumed in its natural form.28 The patient would chew 
the poppy plant, or dissolve it in alcohol and drink the liquid, which limited the absorption 
and impact of the active ingredient.29 Through advances in chemistry, the active 
component of opium—morphine—was identified and isolated.30 Morphine, so named 
after the Greek god of dreams,31 was discovered by a pharmacist in Germany in 1805.32
Following the development of the hypodermic needle and syringe in the 1850s, morphine 
use in the medical field became widespread.33
Scientific researchers and the medical community hoped that morphine would be 
 20. This Comment does not trivialize the enormous toll of OUD and the current opioid epidemic. However, 
the names that humanity has given opioids (“Hul Gil,,” meaning plant of joy, and Heroin, after the “German term 
heros”) illustrates our failure to appreciate the devastating consequences of misuse. See Andrew Rosenblum, et 
al., Opioids and the Treatment of Chronic Pain: Controversies, Current Status, and Future Directions, 16  
EXPERIMENTAL CLINICAL PSYCHOPHARMACOLOGY 405 (2008);Walter Sneader, The Discovery of Heroin, 352
LANCET 1697 (1998).
 21. ROBERT T. GUNTHER, THE GREEK HERBAL OF DIOSCORIDES, BOOK IV 473 (1968). 
 22. Hamilton & Baskett, supra note 4, at 368. 
23. Id.
24. Id.
 25. Rosenblum, et al., supra note 20, at 405. 
26. Id.
 27. Id.
 28. David F. Musto, Opium, Cocaine and Marijuana in American History, 265 SCI. AM. 40, 40 (1991). 
29. Id.
30. Id.
 31. See Hamilton & Baskett, supra note 4. 
 32. Hamilton & Baskett, supra note 4, at 369. 
33. Id.
5
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free from the abuse-potential seen with opium.34 As the active component of opium, a 
smaller amount of drug could be used to produce the same effect.35 However, morphine 
addiction grew quickly.36 This led scientists to search for new compounds that were more 
potent or less addictive. In September 1898, Bayer Company introduced heroin and 
promoted it as “more effective and less addictive than morphine.”37 It was a short-lived 
marketing campaign. 
ii. The Pharmacology, Physiology, and Psychology of Opioid Use Disorder 
Illustrates the Difficulty of Drafting Effective Drug Control Laws38
“Presently she cast a drug into the wine of which they drank to lull all pain and anger 
and bring forgetfulness of every sorrow.”39
Opium is the precursor to modern day opioids,40 with morphine as the primary active 
component of opium.41 Opioid is a term which refers to all chemical compounds that bind 
to opioid receptors.42 Several opioid medications have been developed in an attempt to 
improve upon morphine.43 These include heroin, oxycodone, hydrocodone, codeine, and 
fentanyl.44 Opioids bind to opioid receptors, initiating a cascade of chemical reactions in 
the brain, to produce pain relief.45
The degree to which an opioid “activates” an opioid receptor determines the 
magnitude of effect the drug produces. A full opioid agonist46 is capable of fully activating 
an opioid receptor.47 Higher doses of a full agonist results in full activation of a greater 
number of opioid receptors, giving a greater effect.48 Partial opioid agonists have a limited 
ability to activate an opioid receptor and result in more limited effect.49 A partial opioid 
agonist will result in lower levels of pain relief but also in lower levels of side effects, such 
as less respiratory depression and less euphoria.50
Endorphins are chemical molecules produced by the body involved in pain 
 34. Brownstein, supra note 5, at 5391. 
 35. Musto, supra note 28, at 42. 
 36. Brownstein, supra note 5, at 5391. 
 37. Rosenblum, et al., supra note 20, at 406. 
 38. This section is provided as a brief overview of the biology of opioid use to aid in understanding the scope 
of the opioid epidemic.
 39. Mark-Antoine Crocq, Historical and cultural aspects of man’s relationship with addictive drugs, 9 
DIALOGUES IN CLINICAL NEUROSCIENCE 355, 356 (2007). 
 40. Brownstein, supra note 5, at 5392. 
 41. George B. Stefano, Reciprocal Evolution of Opiate Science from Medical and Cultural Perspectives, 23 
MED. SCI. MONITOR 2890, 2892 (2017). 
 42. Rosenblum, et al., supra note 20, at 406. 
 43. Stefano, supra note 41, at 2890. 
44. Rosenblum, et al., supra note 20, at 406.
45. Stefano, supra note 41, at 2893.
 46. An agonist is a drug that binds to a receptor and produces the same effect as the chemical naturally 
produced by the body. A partial agonist binds to the receptor but produces a smaller effect. This reduced effect 
cannot be overcome by higher doses. See Rosenblum, et al., supra note 20, at 407. 
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management and the internal reward system.51 Endorphins play an important role in 
positive reinforcement for behaviors such as sex, eating, and drinking.52 Research has 
shown that morphine is chemically similar to endorphins.53 The discovery that endorphins 
and morphine exhibit similar effects has aided research into opioid misuse and addiction.54
Opioid receptors are found in tissues throughout the bodies of all mammals as well 
as in various species from other phyla.55 Studies have also shown that nervous system 
tissue from invertebrates contains multiple types of opioid receptor, indicating that opioid 
receptor expression is an evolutionarily conserved trait that predates the separation of 
vertebrates and invertebrates.56
While several subtypes of opioid receptors exist, most opioid pain medications exert 
their effect by activating the mu opioid receptor.57 This activation is significant due to the 
role the mu receptor plays in the reward system of the brain.58 Activity that results in 
activation of the reward system is positively reinforced, increasing the desire to repeat the 
activity.59 In some individuals, this reward system activation leads to a dramatically 
increased desire to repeat the activity, which can result in OUD.60 Repeated activation of 
the reward system by opioids is also associated with withdrawal symptoms, such as 
irritability and diarrhea.61
The problem of reward system activation is compounded when an individual 
misuses a short-acting opioid, such as heroin.62 “Heroin has a short half-life”63 and the 
euphoric feeling associated with use diminishes quickly.64 An individual needs to take 
repeated doses to maintain the pleasurable feelings and avoid withdrawal symptoms.65
Tolerance can also quickly develop, resulting in a need for increased amounts of drug to 
achieve the same effect.66 This cycle of highs and lows can lead to a continuous need for 
ever increasing amounts of the drug.67
 51. Adam S. Sprouse-Blum, et al., Understanding Endorphins and Their Importance in Pain Management,
69 HAW. MED. J. 70 (2010). 
52. Id. 
 53. Stefano, supra note 41, at 2890. 
54. Id. at 2894. 
55. Id. at 2893–94. 
 56. Glossary, MOUSE GENOME INFORMATICS,
http://www.informatics.jax.org/glossary/evolutionary_conservation (last visited Nov. 27, 2019) (Evolutionary 
conservation is defined as “[t]he presence of similar genes, portions of genes, or chromosome segments in 
different species, reflecting both the common origin of species and an important functional property of the 
conserved element.”); see Stefano, supra note 41, at 2893. 




 61. American College of Obstetricians and Gynecologists, ACOG Committee Opinion: Opioid Use and 
Opioid Use Disorder in Pregnancy, 130 OBSTETRICS & GYNECOLOGY e81, e84 (2017) [hereinafter ACOG]. 
62. Id. 
 63. Id. In pharmacology, half-life refers to the amount of time for the amount of drug in the body to be 
reduced by one-half. If an individual takes 10mg of a drug with a two-hour half-life, after four hours only 25% 
of the drug will remain. The shorter the half-life the shorter the duration of effect. 
 64. Id.
65. Id. 
 66. Rosenblum, et al., supra note 20, at 408. 
67.    Id.
7
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iii. Opioid Use Disorder and the Opioid Crisis—Physicians Pivot to Overusing 
Opioids as the Focus Shifts to Pain Control and Patient Satisfaction 
OUD is characterized as a “problematic pattern of opioid use leading to clinically 
significant impairment or distress . . . .”68 The diagnosis is based on several criteria, 
including unsuccessful efforts to cut down use and failure to fulfill obligations at work, 
school, or home.69 Individuals who abuse or misuse opioids are now viewed as having a 
“chronic, treatable disease” and can “regain control of their health and their lives” with 
proper treatment.70 The medical community, from psychiatrists and mental health 
practitioners71 to obstetricians and gynecologists,72 largely has adopted this view of opioid 
addiction. 
The prior approach to opioids and opioid addiction started with the Harrison 
Narcotic Control Act of 1914, which sought to control widespread use and abuse of 
morphine, cocaine, and heroin.73 The Act resulted in a general distrust of opioids by 
physicians and patients alike.74 This belief persisted for decades.75 Physicians were 
reluctant to prescribe opioids for long periods of time over concerns about addiction.76 A 
seminal study was published in 1973.77 This study noted that seventy-three percent of 
patients treated in a hospital setting experienced undertreated moderate-to-severe pain.78
The study concluded that physicians had poor knowledge of pain control treatment 
options.79 In 1990, the president of the American Pain Society wrote an editorial that 
asserted, without evidence, that the “[t]herapeutic use of opiate analgesics rarely results in 
addiction.”80 This assertion was a departure from the practice that persisted in the 
American medical community for decades.81
The federal government also played a role, perhaps unwittingly, in encouraging the 
current opioid epidemic. The Centers for Medicare and Medicaid Services (“CMS”) 
publish standards that health care organizations must meet in order to receive federal 
funding. The Joint Commission is a nonprofit organization that accredits healthcare 
 68. AM. PSYCHIATRIC ASS’N, DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS 541 (5th ed. 
2013) (chapter discussing opioid use disorder diagnostic criteria) [hereinafter APA]. 
69. Id. 
 70. ACOG, supra note 61, at e82.  
 71. APA, supra note 68, at 543. 
 72. ACOG, supra note 61, at e82–e83.  
 73. Jones, et al., supra note 9, at 15. 
74. Id. 
 75. Rosenblum, et al., supra note 20, at 406. 
76. Id. at 405. 
 77. Richard Marks & Edward Sachar, Undertreatment of Medical Inpatients with Narcotic Analgesics, 78 
ANNALS INTERNAL MED. 173 (1973). 
78. Id. at 175. 
79. Id. at 180–81. 
 80. Mitchell B. Max, Improving Outcomes of Analgesic Treatment: Is Education Enough?, 113 ANNALS 
INTERNAL MED. 885, 885 (1990); see also Jane Porter & Hershel Jick, Addiction Rare in Patients Treated with 
Narcotics, 303 N. ENGL. J. MED. 123 (1980) (An editor’s note on the journal website includes a disclaimer for 
this letter); U.S. SENATE HOMELAND SEC. & GOV’T AFFAIRS COMM., FUELING AN EPIDEMIC: REPORT TWO 4 
(2017) (A 2017 government report noting that the American Pain Society received over nearly a million dollars 
from opioid pharmaceutical manufacturers over a five year period.) 
 81. Jones, et al., supra note 9, at 15. 
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organizations.82 The Joint Commission performs onsite investigations to determine 
whether healthcare systems are in compliance with the Commission’s standards. These 
standards reflect CMS requirements, as well as new and emerging standards of care.83 Joint 
Commission accreditation is extremely important to healthcare organizations: receiving 
accreditation provides eligibility to participate in Medicare and Medicaid, the largest 
purchasers of healthcare services in the country.84
In 2000, the Joint Commission85 published new standards for pain management.86
The updated standards from the Commission were largely consistent with the 
recommendations from the American Pain Society. In its recommendations, the APS 
argued for treating “pain as the fifth vital sign” and encouraged a more liberal approach to 
prescribing opioids.87 New approaches to gauge pain were implemented, such as the 
numeric pain scale.88 Joint Commission recommendations encouraged practitioners to 
screen all patients for pain, potentially increasing the likelihood that a patient would 
receive an opioid prescription.89 Practitioners and nursing staff also mistakenly viewed 
“pain as the fifth vital sign” as a literal command to check pain levels each time vital signs 
were taken.90 Physicians that did not adequately control a patient’s pain risked legal action 
for substandard care.91
Perhaps not coincidentally, “overdoses related to opioid pills, started rising in the 
year 2000 . . . .”92 As the focus changed to patient satisfaction, which placed a heavy 
emphasis on pain management, health care providers felt pressure to treat pain more 
 82. Joint Commission FAQs, JOINT COMM’N, https://www.jointcommission.org/about-us/facts-about-the-
joint-commission/joint-commission-faqs/ (last visited Jan. 12, 2020). 
    83.   Id.
84. See Why Achieve Accreditation? JOINT COMM’N, https://www.jointcommission.org/accreditation-and-
certification/become-accredited/why-achieve-accreditation/ (last visited Nov. 16, 2020); see also What is the 
difference between Medicare and Medicaid?, HHS, https://www.hhs.gov/answers/medicare-and-medicaid/what-
is-the-difference-between-medicare-medicaid/index.html (last visited Nov. 21, 2019). Medicare and Medicaid 
are the two largest federal health care programs. Both are administered by the Centers for Medicare and Medicaid, 
an agency within the Department of Health and Human Services. Medicare is an insurance program that primarily 
covers persons over 65 years-old and certain disabled younger persons. Medicaid is a federal assistance program 
that provides health care coverage for persons with very low incomes. 
 85. Id. The Joint Commission is a hospital accrediting body. Accreditation by the Joint Commission is vital 
for a hospital to receive federal funding, which constitutes the largest portion of the budget of many hospitals. 
 86. Jones, et al., supra note 9, at 15. 
 87. See Ill. Pub. Risk Fund v. Purdue Pharma L.P., 2019 WL 3080929 (N.D. Ill. July 15, 2019). (American 
Pain Society is listed as one of the “Front Group Defendants,” essentially asserting that the society was a front 
group for opioid manufacturers, promoting their products while claiming to be an independent medical 
membership organization.); Jones, et al., supra note 9, at 15; see also Teresa Rummans, et al., How Good 
Intentions Contributed to Bad Outcomes: The Opioid Crisis, 93 MAYO CLIN. PROC. 344–47 (2017). 






 91. Kathryn L. Tucker, Medico-Legal Case Report and Commentary: Inadequate Pain Management in the 
Context of Terminal Cancer. The Case of Lester Tomlinson, 5 PAIN MED. 214, 214–15 (2004). 
 92. Daniel Ciccarone, The Triple Wave Epidemic: Supply and Demand Drivers of the US Opioid Overdose 
Crisis, 71 INT’L J. DRUG POL’Y 183–88, https://doi.org/10.1016/j.drugpo.2019.01.010 (last visited Sept. 21, 
2019). 
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aggressively.93 The HCAHPS (Hospital Consumer Assessment of Healthcare Providers 
and Systems) survey collects information on patient satisfaction with hospital care.94
Participation in the survey is another requirement for hospitals to receive full 
reimbursement from federal health care programs.95 In the mid-2000s, when the survey 
was introduced, assessment of patients’ satisfaction with pain control was heavily 
weighted.96
B. Telemedicine Has the Potential to Dramatically Impact the Future of Addiction 
Treatment by Connecting Providers with Patients Regardless of Location 
i. Defining “Telemedicine”—More Than a Phone Call with the Doctor 
The basic idea of telemedicine—delivering health care information across 
distances—reaches back in human history.97 The ancient Greeks used smoke signals and 
reflected sunlight to communicate information about the outbreak of disease and the need 
for physicians.98 Telemedicine is a “method of practicing medicine in which the physician 
is at one geographical location, the patient is at a different geographical location, and the 
two communicate through a secure electrical audio-visual connection.”99 The Federal 
Communications Commission definition includes “facilitating access to specialists that are 
not located in the same place as the patient.”100 That aspect of telemedicine—connecting 
patients with mental health practitioners and addiction specialists—is a pressing need 
nationally.101
Telemedicine is a subset of telehealth, a term that also includes services such as 
patient education and medication adherence counseling.102 Telehealth also includes 
patient monitoring functions and patient education, such as a nurse instructing a patient on 
how to use a piece of medical equipment.103 Telecare, a more general topic, encompasses 
items and services that patients can use on their own. It includes things such as fitness apps 
and sensors and digital medication reminder devices.104
 93. Rummans, et al., supra note 87, at 346–47 . 
94. Id. at 346. 
95. Id. at 347. 
96. Id.
97. History of Telemedicine, MDPORTAL, http://mdportal.com/education/history-of-telemedicine. 
98. Id.
 99. Planned Parenthood of the Heartland, Inc. v. Iowa Bd. of Med., 865 N.W.2d 252, 255 (Iowa 2015). 
 100. FCC, supra note 11. 
 101. NAT’L COUNCIL FOR BEHAV. HEALTH, THE PSYCHIATRIC SHORTAGE: CAUSES AND SOLUTIONS 2 (Mar. 
28, 2017), https://www.thenationalcouncil.org/wp-content/uploads/2017/03/Psychiatric-Shortage_National-
Council-.pdf; see also Samantha Raphelson, Severe Shortage of Psychiatrists Exacerbated by Lack of Federal 
Funding, NPR (Mar. 9, 2018), https://www.npr.org/2018/03/09/592333771/severe-shortage-of-psychiatrists-
exacerbated-by-lack-of-federal-funding. 
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Telemedicine has shown great potential to cut costs105 and improve care.106 The 
functions listed above can allow a patient to avoid trips to a physician’s office or 
hospital.107 By allowing instant and convenient access to a physician, telemedicine can 
reduce the length of hospital stays or eliminate some hospital admissions altogether.108
For example, the Veterans Health Administration experienced great success in treating 
patients when it introduced a telemedicine program in 2003.109 The program enrolled 
veterans with chronic conditions aiming to avoid costly admission to long-term care 
facilities.110 The program increased from two thousand patients in 2003 to over thirty 
thousand patients in 2007.111 The program had a cost of one thousand six hundred dollars 
per year, compared to long-term care costs that averaged over seventy-seven thousand 
dollars per year.112
ii. Federal Regulation of Telemedicine Would Overcome Barriers Created by the 
State-by-State Approach of Medical Licensure 
The practice of medicine, as well as telemedicine, is regulated on a state-by-state 
basis.113 Some states have adopted policies that promote the use of telemedicine while 
others have imposed restrictions on the practice.114 These mixed approaches have led to a 
patchwork of regulations that impose substantial burdens on practitioners and deprive 
patients of access to care.115
Some states impose limits on the practice of telemedicine by requiring practitioners 
to personally examine patients prior to making a diagnosis.116 This restriction is similar to 
federal prohibitions on controlled substances prescriptions issued without an in-person 
exam.117 There is also case law that demonstrates state medical boards, composed 
primarily of practicing physicians, promulgated rules to limit the use of telemedicine to 
105. See Adam Darkins, et al., Care Coordination/Home Telehealth: The Systematic Implementation of Health 
Informatics, Home Telehealth, and Disease Management to Support the Care of Veteran Patients with Chronic 
Conditions, 14 TELEMEDICINE & E-HEALTH 1118, 1125 (2009); see also Steff Deschenes, 5 ways telemedicine 
is driving down healthcare costs, HEALTHCARE IT NEWS (July 16, 2012), 
https://www.healthcareitnews.com/news/5-ways-telemedicine-driving-down-healthcare-costs; Susan Morse, 
Telehealth eliminates time and distance to save money, HEALTHCARE FIN. (Oct. 16, 2019), 
https://www.healthcarefinancenews.com/news/telehealth-eliminates-time-and-distance-save-money; Jack E. 
Russo, et al., VA Telemedicine: An Analysis of Cost and Time Savings, 22 TELEMEDICINE & E-HEALTH No. 3 
(2016), http://online.liebertpub.com/doi/abs/10.1089/tmj.2015.0055#utm_source=ETOC&utm_ 
medium=email&utm_campaign=tmj. 
 106. Jami L. Dellifraine & Kathryn H. Dansky, Home-based telehealth: a review and meta-analysis, 14 J.
TELEMEDICINE & TELECARE 62 (2008). 
 107. Jay M. Zitter, Regulation of and Liability Arising from Telemedicine, 23 A.L.R. 7th Art. 5, 2 (2017). 
108. Id. 




113. See generally FSMB, http:www.fsmb.org/. 
 114. U.S. DEP’T OF HEALTH & HUMAN SERVS. & THE HEALTH RES. & SERVS. ADMIN., HEALTH LICENSING 
BOARD REPORT TO CONGRESS 6 (2011). 
 115. FEDERAL COMMC’NS COMM’N, CONNECTING AMERICA: THE NATIONAL BROADBAND PLAN 206 (2010), 
https://transition.fcc.gov/national-broadband-plan/national-broadband-plan.pdf. 
 116. Zitter, supra note 107, at 2. 
 117. 21 U.S.C. § 829(e). 
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protect the interests of local physicians.118
Following the spread of telemedicine, there has been a push to regulate telemedicine 
at the federal level.119 The licensure of pilots is an instructive analogy.120 Pilots routinely 
and necessarily cross state boundaries. State-by-state regulation would lead to a 
fragmented and inefficient system that would greatly limit air travel. These same concerns 
are true for the regulation of telemedicine. Since telemedicine very likely to cross state 
lines, federal regulation would eliminate uncertainty for the urban physician with more 
specialized expertise treating a telemedicine patient who lives in a rural area in an adjacent 
state.
States are also historically protectionist when professional licensure issues are 
involved. In 2001, Oklahoma refused to join the Nurse Licensing Compact, which would 
allow for reciprocity of nursing licenses between states, because it would “authorize[] the 
legislatures of other states to determine . . . the qualifications of persons admitted to 
practicing nursing in Oklahoma.”121 Federal regulation would avoid this protectionism 
and allow for uniformity in standards and application.122 This uniformity would increase 
access to physicians and, importantly, specialists for patients living in rural or otherwise 
underserved areas.  
Another issue facing practitioners is reimbursement for services provided via 
telemedicine. As the largest purchaser of professional health care services, restrictions 
placed on telemedicine by Medicare have far reaching implications.123 Medicare provides 
payment for telemedicine services in very limited circumstances.124 Currently, patients 
must reside in federally designated rural areas in order to qualify for Medicare reimbursed 
telemedicine services.125 This artificial limitation imposes unnecessary burdens on 
patients living in rural areas that fall outside a federally designated area, or rural areas that 
are near a large urban area.126 Since one in three patients is covered by Medicare,127 limits 
on reimbursement discourage practitioners from adopting telemedicine services into their 
practices.
One final consideration for telemedicine providers and policymakers is the impact 
118. See Teladoc, Inc. v. Tex. Med. Bd., 453 S.W.3d 606 (Tex. App. 2014). 
 119. Bill Marino, et al., A Case for Federal Regulation of Telemedicine in the Wake of the Affordable Care 
Act, 16 COLUM. SCI. & TECH. L. REV. 274 (May 17, 2015). 
120. Id. at 284–85. 
121. Id. at  286. 
122. Id. 
 123. Centers for Medicare and Medicaid Services, CMS Roadmaps Overview,
https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-
Instruments/QualityInitiativesGenInfo/Downloads/RoadmapOverview_OEA_1-16.pdf [hereinafter CMS 
Roadmap]. 
 124. Mandy Bell, et al., Geographic Restrictions for Medicare Telehealth Reimbursement (May 2011), 
https://www.ruralhealthweb.org/getattachment/Advocate/Policy-
Documents/GeographicRestrictionsforMedicareReimbursementPolicyPaper.pdf.aspx?lang=en-US; see also 
mHealthIntelligence, CMS Finalizes Telehealth Expansion for Medicare Advantage Plans (Apr. 8, 2019), 
https://mhealthintelligence.com/news/cms-finalizes-telehealth-expansion-for-medicare-advantage-plans (CMS 
has published rules effective in 2020 that will expand access to telehealth services for individuals enrolled in 
Medicare Advantage plans, which cover about thirty percent of Medicare beneficiaries.). 
 125. Bell, et al., supra note 124. 
126. Id. 
 127. CMS Roadmap, supra note 123. 
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of the Health Insurance Portability and Accountability Act’s (“HIPAA”) Privacy and 
Security Rules. Providers should be aware that the methods used to communicate 
electronic protected health information (“ePHI”) must remain secure.128 HIPAA 
guidelines on telemedicine state “(1) only authorized users should have access to ePHI; 
(2) a system of secure communication should be implemented to protect the integrity of 
ePHI; and (3) a system of monitoring communications containing ePHI should be 
implemented to prevent accidental or malicious breaches.”129 HIPAA broadly governs the 
protection of personal health information, with restrictions on disclosures of information 
as well as standards for physician and electronic security. 
iii. As an Activity That Will Necessarily Cross State Lines, Jurisdictional Issues 
for Telemedicine Abound 
One of the most notable issues surrounding telemedicine is the ease with which it 
allows the practice of medicine to cross state lines. State laws permitting or restricting the 
practice of telemedicine are tasked with determining where the practice occurs. Does it 
occur where the physician is located, and likely licensed? Or does it occur wherever the 
patient happens to be, regardless of where the physician is licensed or located?  
These questions do not have simple answers. Several laws have been proposed to 
increase access to telemedicine services that cross state lines.130 States have historically 
argued that the regulation of health care professionals falls under the Police Power of the 
Tenth Amendment.131 This argument has been weakened over several decades by the 
federal government’s extensive involvement in health care.132 The Controlled Substances 
Act (“CSA”) greatly impacts the practice of medicine, as it limits what medications can 
be prescribed by state-licensed health professionals. The CSA also regulates the in-state 
production of controlled substances. In Gonzales v. Raich, the Supreme Court upheld part 
of the CSA that criminalizes the home production of marijuana, which California had 
legalized for medicinal purposes.133 The majority in Gonzales found that the CSA was 
within Congress’s authority to regulate interstate commerce.134 Viewing telemedicine as 
an activity, like the manufacture and distribution of controlled substances, which will 
undoubtedly impact interstate commerce, federal regulation seems appropriate. 
 128. HIPAA Guidelines on Telemedicine, HIPAA J., https://www.hipaajournal.com/hipaa-guidelines-on-
telemedicine/. 
129. Id.
130. See generally TELE-MED Act of 2013, H.R. 3077, 113th Cong. (2013); Telehealth Enhancement Act of 
2014, S. 2662, 113th Cong (2014). 
 131. Marino, et al., supra note 119, at 297; see also Wendy Parmet, Regulation and Federalism: Legal 
Impediments to State Health Care Reform, 19 AM. J. L. & MED. 121, 123 (1993) (citing Mugler v. Kansas, 123 
U.S. 623, 659 (1887)) (the Police Power derives from the “ancient power of sovereigns to regulate their internal 
affairs to ensure the health and safety of the citizenry,” and is defined as the “right of the States of the Union . . . 
to protect the health, morals, and safety of their people by regulations . . . .”). 
132. E.g., Federal Food, Drug, and Cosmetic Act, Pub. L. No. 75-717; Health Insurance Portability and 
Accountability Act of 1996, Pub. L. No. 104-191. 
 133. See generally 545 U.S. 1 (2005). 
134. Id. at 22. 
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III. CONGRESS ATTEMPTS TO CONTROL ACCESS TO THE MOST ADDICTIVE SUBSTANCES 
EVER DISCOVERED
A. The Federal Government’s Many Approaches to Controlled Substances
i. The Harrison Narcotics Tax Act of 1914  
In 1914, Congress passed the Harrison Narcotics Tax Act.135 The Act passed in 
response to the “sudden emergence of street heroin” and widespread prescription morphine 
abuse.136 The Act sought to control the widespread use and abuse of opioids, often 
obtained from a physician or pharmacist.137 The Act restricted the prescribing and 
dispensing of “opium or cocoa leaves”138 or any derivatives.139 Physicians were allowed 
to prescribe opium or cocoa leaves, or derivatives, in the “course of his professional 
practice only.”140
Through its Taxing Power, Congress imposed a small tax on each transfer of 
opioids.141 In order to pay the tax, health care providers registered with and obtained a 
permit from the Treasury Department.142 This registration requirement successfully 
compelled physicians and pharmacists to account for the quantities of opioids they were 
dispensing to patients.143 The Act also required that dispensing records be maintained for 
inspection by government officials.144
In short order, negative consequences of the Act emerged. Physicians who provided 
OUD treatment were prosecuted for failing to “attempt to cure the morphine habit” and 
for dispensing or prescribing outside the scope of professional practice.145 With physicians 
unwilling or unable to supply prescription opioids, most patients were forced to use 
underground opioid markets.146 Until the passage of the Controlled Substances Act of 
1970, this policy of limiting access to all opioids would continue. 
ii. The Controlled Substances Act 
The Controlled Substances Act (“CSA”), officially known as the Federal 
Comprehensive Drug Abuse Prevention and Control Act of 1970, became effective in 
 135. Jones, et al., supra note 9, at 15. 
136. Id. 
 137. Musto, supra note 28, at 40. 
 138. It is worth noting that derivatives of “opium and cocoa leaves” are pharmacologically distinct. One is a 
depressant, the other a stimulant. They were combined because of the assumption that both were addictive, 
associated with crime, and could get the user “high.” Marijuana would also later be classified as a narcotic for 
similar reasons. See COMM.  FOR THE SUBSTANCE COVERAGE STUDY DIV. OF HEALTH CARE SERVS., INST. OF 
MED., TREATING DRUG PROBLEMS VOL. 2 (Dean R. Gerstein & Henrick J. Harwood eds., 1992). 
 139. The Harrison Narcotic Act of 1914, Pub. L. No. 63-223, 785 (1914). 
140. Id. at 786. 
 141. Musto, supra note 28, at 40. 
142. Id.
143. Id. 
 144. The Harrison Narcotic Act of 1914, Pub. L. No. 63-223, 786 (1914). 
 145. Webb v. United States, 249 U.S. 96, 98 (1919). 
 146. Jeremy Lesser, Today is the 100th Anniversary of the Harrison Narcotics Tax Act, DRUG POL’Y
ALLIANCE (Dec. 16, 2014), http://www.drugpolicy.org/blog/today-100th-anniversary-harrison-narcotics-tax-act. 
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1971.147 It represents a broad attempt by Congress, through its Commerce Clause 
power,148 to regulate the manufacture and distribution of controlled substances.149 The 
CSA, codified at 21 U.S.C. § 801 contains three titles, each with a different focus.150 Of 
importance to this comment, Title II addresses the registration, manufacture, and 
distribution of controlled substances.151 The Drug Enforcement Agency is the federal 
agency charged with enforcing the provisions of the Act.152
The CSA categorizes medications into five schedules based on abuse potential and 
accepted medical use.153 The Attorney General, in collaboration with the Secretary of the 
Department of Health and Human Services, determines a medication’s schedule.154
Medications determined to have a high abuse potential and no acceptable medical use are 
placed in the highest schedule, Schedule I.155 This list includes drugs such as heroin, 
marijuana, ecstasy and LSD.156 Medications listed in Schedule I may not be prescribed by 
physicians, and research using those medications is heavily restricted. Medications 
determined to have a lower abuse potential, such as oxycodone or Adderall, are placed in 
Schedule II.157 Physicians are allowed to prescribe drugs in this schedule, although there 
are significant restrictions.158 Drugs with lower abuse potential are placed in lower 
schedules with fewer restrictions.159 Drugs with no abuse potential are excluded from 
regulation by the CSA.160
The CSA makes it unlawful for any person to knowingly or intentionally 
manufacture, distribute, or dispense a controlled substance.161 It also bars the creation, 
possession, or distribution of counterfeit controlled substances.162 Under 21 U.S.C. § 846, 
attempts and conspiracies to violate provisions of the CSA are punished with the same 
penalty as the attempted or conspired offense.163 To add teeth to the regulations governing 
the manufacture and distribution of controlled substances, the CSA imposes severe 
penalties.164 Violations of the CSA can incur substantial prison terms.165 Violators may 
 147. Michael Gabay, The Federal Controlled Substances Act: Schedules and Pharmacy Registration, 48 
HOSP. PHARM. 473 (2013). 
 148. 21 U.S.C. § 801(3) 
 149. Gabay, supra note 147, at 473. 
150. Id. 
151. Id. 
 152. OFFICE OF DIVERSION CONTROL, DRUG ENF’T AGENCY, PHARMACIST’S MANUAL: AN INFORMATIONAL 
OUTLINE OF THE CONTROLLED SUBSTANCES ACT 3 (2010), 
https://www.deadiversion.usdoj.gov/pubs/manuals/pharm2/pharm_manual.pdf. 
 153. 21 U.S.C. § 811(c). 
 154. Gabay, supra note 147, at 473. 
155. Id. at 473–74. 
 156. 21 U.S.C. § 812(c). 
157. Id. (Medications are listed by chemical name, which may differ greatly from the common brand or generic 
names). 
 158. Id. § 812(b). 
 159. Id. § 812(c). 
 160. Id. § 811(c)(1). 
 161. 21 U.S.C. § 841(a)(1). 
 162. Id. § 841(a)(2). 
 163. Id. § 846. 
 164. 21 U.S.C. § 841(b). 
 165. Brian T. Yeh, Cong. Research Serv., RL30722, Drug Offenses: Maximum Fines and Terms of 
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be charged with offenses ranging from drug trafficking166 to environmental damage167
and illegal manufacturing168 to money laundering.169 Penalties range from fines to 
imprisonment and even death.170
iii. The Narcotic Addict Treatment Act of 1974 
The CSA was an acknowledgement by the federal government that some opioids 
serve a legitimate purpose and regulated access would be beneficial. However, the federal 
stance on OUD treatment remained unchanged. From the time of the Harrison Narcotics 
Act, physicians were barred from using legal opioids to treat patients with OUD.  
The Narcotic Addict Treatment Act of 1974 (“NATA 1974”) amended the CSA to 
place restrictions on physicians who prescribed narcotics for maintenance or detoxification 
treatment of opioid addiction.171 The changes required physicians who dispense narcotic 
drugs to individuals for maintenance or detoxification treatment172 to obtain a special 
registration from the DEA.173 Physicians were also limited in the amount of methadone 
they could provide to patients for at-home use.174 In the 1970s, medical treatment of opioid 
addiction was limited to “methadone clinics,” where patients were administered a dose of 
medication.175 This tight regulation and requirement of daily dosing limited the number 
of patients treated and contributed to the stigma of opioid addiction treatment.176
iv. Laws Expanding Access to OUD Treatment—The Drug Addiction Treatment 
Act of 2000 and The Comprehensive Addiction and Recovery Act of 2016 
The Drug Addiction Treatment Act of 2000 (“DATA 2000”) allowed physicians to 
seek a special registration to prescribe buprenorphine177 as part of an in-office medication-
Imprisonment for Violation of the Federal Controlled Substances Act and Related Laws (2015). 
 166. See generally 21 U.S.C. § 841. 
 167. Id. § 841(b)(6). 
 168. 18 U.S.C. § 1956. 
 169. Id.
 170. 21 U.S.C. § 841(b). 
 171. The Narcotic Addict Treatment Act of 1974 (P.L. 93-281). 
 172. 21 U.S.C. §§ 802(29)-(30). Maintenance treatment is “the dispensing, for a period in excess of twenty-
one days, a narcotic drug in the treatment of an individual for dependence on heroin or other morphine-like drugs. 
Detoxification treatment is “the dispensing, for a period not in excess of twenty-one days of a narcotic in 
decreasing doses to an individual in order to alleviate adverse physiological or psychological effects incident to 
withdrawal from the continuous or sustained use of a narcotic drug and as a method of bringing the individual to 
a narcotic drug-free state.” Id.
 173. Id. § 823(g)(1). 
 174. FEDERAL REGULATION OF METHADONE TREATMENT 96 (Richard Rettig & Adam Yarmolinsky eds., 
1995). 
 175. Ellen M. Weber, Failure of Physicians to Prescribe Pharmacotherapies for Addiction: Regulatory 
Restrictions and Physician Resistance, 13 J. HEALTH CARE L. & POL’Y 49, 54 (2010) (citing Michael Weinrich 
& Mary Stuart, Provision of Methadone Treatment in Primary Care Medical Practices: Review of the 
Scottish Experience and Implications for US Policy, 283 JAMA 1343, 1343–44 (2000)). 
 176. Kevin Fiscella, Deregulating Buprenorphine Prescribing for Opioid Use Disorder Will Save Lives,
https://www.statnews.com/2019/03/12/deregulate-buprenophine-prescribing/. 
 177. Buprenorphine is an opioid that binds tightly to the opioid receptor. Since it binds tightly, it prevents use 
of other opioids. However, since it does not fully activate the mu receptor, it does not produce the euphoric 
“high” associated with other opioids. Hendree E. Jones, Practical Considerations for the Clinical Use of 
Buprenorphine, 2 SCI. & PRAC. PERSP. 4, 5 (2004). 
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assisted treatment (MAT) program. DATA 2000 greatly expanded access to MAT therapy. 
Patients were no longer required to seek treatment from a federal drug treatment program. 
Physicians are required to undergo additional training in order to register.178 The statute 
also limits the number of patients a physician may treat with MAT.179 Registration was 
also limited to physicians. Nurse practitioners and physician assistants were excluded.180
This limitation disproportionally impacted patients living in rural areas who often lack 
access to physicians and are increasingly served by mid-level practitioners.181
While DATA 2000 increased the availability of office-based MAT therapy, access 
was still negatively impacted by the limits on the types of practitioners and the number of 
patients. The Comprehensive Addiction and Recovery Act of 2016 (“CARA 2016”) 
sought to improve access to the in-office MAT therapy allowed by DATA 2000.182 CARA 
2016 amended the CSA to include qualified nurse practitioners and physician assistants 
among those practitioners able to prescribe buprenorphine for office-based MAT 
therapy.183 The increase in available practitioners expanded access for patients seeking 
treatment. 
B. A Tragic Event and a Well-Intentioned Reaction 
In the late 1990’s, the internet boom allowed for the development and proliferation 
of internet pharmacies.184 These pharmacies set up websites to promote their services and 
to interact with potential patients.185 The websites used metatags such as “hydrocodone 
no prescription”186 and search engine optimization services from companies like Google 
to make their services easier to find.187 Internet pharmacies used these websites to collect 
patient data, such as mailing address and payment information, and to host an online 
questionnaire: the online questionnaire served as the basis for the prescription order.188
The basic operation of these pharmacies followed a similar formula. A patient visited 
the website and completed the online questionnaire.189 The patient indicated his desired 
medication and submitted the completed questionnaire.190 Those answers were forwarded 
to a contracted physician who, after a cursory review, issued a prescription for the desired 
medications.191 That prescription was sent to the pharmacy’s physical location to be filled 
 178. 21 U.S.C. § 823(g)(2)(G). 
 179. Id. § 823(g)(2)(B)(iii). 
 180. Originally, the definitions used at 21 U.S.C. § 823(g)(2)(G) only included “physicians.”
 181. Hilary Barnes, Michael R. Richards, Matthew D. McHugh & Grant Martsolf, Rural And Nonrural 
Primary Care Physician Practices Increasingly Rely On Nurse Practitioners, 37 HEALTH AFFAIRS 6 (2018). 
 182. 21 U.S.C. § 823(g)(2)(G). 
 183. Id.
 184. Camille Guerra & Timothy Mackey, USA Criminal and Civil Prosecutions Associated with Illicit Online 
Pharmacies: Legal Analysis and Global Implications, 1 MA@POC 104 (2017). 
185. See United States v. Darji, 609 Fed. Appx. 320 (6th Cir. 2015) (offering a full description of the typical 
“internet” pharmacy operation). 
186. Id. at 323. 
 187. Guerra, supra note 184, at e115. 
188. Darji, 609 Fed. Appx. at 323. 
189. Id.
190. Id.
191. Id. at 323–24. 
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and mailed to the patient.192
Ryan Haight was a high school senior who purchased hydrocodone from an online 
pharmacy.193 He died of an overdose of that drug when he was seventeen years old.194
The pharmacy, owned and operated by Clayton Fuchs, maintained a website that provided 
customers an online questionnaire.195 Ryan completed the questionnaire and submitted it 
to the pharmacy’s contracted physician who prescribed the requested medications.196 The 
prescription was forwarded to Fuchs’ pharmacy for dispensing and mailing.197 Ryan and 
the physician never directly interacted.198
The Ryan Haight Online Pharmacy Consumer Protection Act of 2008, commonly 
referred to as the Ryan Haight Act, was passed in response to the tragedy of Ryan’s 
death.199 The Ryan Haight Act sought to ban the online questionnaire and minimal medical 
evaluation format used by illegitimate online pharmacies.200 However, given the 
imprecise language of the statute, along with its narrow and outdated definition of 
telemedicine,201 the Ryan Haight Act has stood in the way of the meaningful adoption and 
use of telemedicine to treat opioid addiction. In a sad bit of irony, an act which was 
designed to decrease opioid misuse operates, in effect, to hinder one method to addressing 
the opioid crisis. 
The Ryan Haight Act amended the CSA to create restrictions on the practice of 
prescribing controlled substances using the internet.202 The Act provides that “[n]o 
controlled substance . . . may be . . . dispensed by means of the Internet without a valid 
prescription.”203 The Act defines a valid prescription for a controlled substance as one 
“issued for a legitimate medical purpose in the usual course of professional practice” by a 
practitioner who has conducted at least one in-person medical evaluation.204 This 
prohibition was specifically aimed at the business model of illicit online pharmacies.205
The Ryan Haight Act also created a state cause of action.206 Under this amendment 
to the CSA, States have the ability to file in federal district court a civil action to seek a 
nationwide injunction against conduct found to violate internet pharmacy regulations.207
States can also claim damages and seek restitution.208 Under the statute, the state must 
192. Id. at 324. 
 193. Bethany Lipman, Note, Prescribing Medicine for Online Pharmacies: An Assessment of the Law and a 
Proposal to Combat Illegal Drug Outlets, 50 AM. L. REV. 545, 545 (2013) 
 194. S. Rep. No. 110-521, at 8 (2008). 
 195. Jeff Karberg, Progress in the Challenge to Regulate Online Pharmacies, 23 J. L. & Health 113, 130 (2010). 
 196. S. Rep. No. 110-521, at 8–9 (2008).  
 197. Id.
 198. Id. 
 199. Id. at 7.  
 200. Id. at 19. 
 201. 21 U.S.C. § 802(54). 
 202. Id. § 829(e). 
 203. Id. § 829(e)(1). 
 204. Id. § 829(e)(2)(A). 
 205. Jeff Karberg, Progress in the Challenge to Regulate Online Pharmacies, 23 J. L. & HEALTH 113, 122 
(2010). 
 206. 21 U.S. C. § 882(c)(1). 
 207. Id. § 882(c)(1)(a). 
 208. Id. § 882(c)(1). 
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provide advanced notice to the federal government, which has the right to intervene and 
be heard on all matters relating to the case.209
The legislative history of the Ryan Haight Act shows the overarching purpose of the 
act was to reduce the incidence of adolescent prescription drug abuse.210 Joseph Califano, 
Chief Executive Officer of the National Center on Addiction and Substance Abuse 
(“CASA”), testified that “the fastest growing drug abuse among our Nation’s children 
involves prescription drugs.”211 During a hearing before the Senate Committee on the 
Judiciary, Francine Haight, Ryan’s mother, testified that “[t]ighter controls on the sale of 
controlled substances on the internet . . . will help.”212
Further testimony addressed the government’s concerns with combating prescription 
drug abuse and the proliferation of illicit online pharmacies. Alberto Gonzales, then 
Attorney General, testified that it was difficult for law enforcement “to track any of the 
individuals behind the websites” because the websites “either posted no information or 
simply gave false information.”213 The Senate report also noted the voluntary nature of 
the method of certifying internet pharmacies.214
IV. A PRESCRIPTION FOR CHANGE
A. Unnecessary Legislation—In an Age of “Internet-based drug trafficking 
organization[s],” “[O]utside the usual course of professional practice” Is Still the 
Standard.  
In Gonzales v. Oregon, the Supreme Court stated that the CSA “bars doctors from 
using their prescription writing powers as a means to engage in illicit drug dealing and 
trafficking as conventionally understood.”215 Several cases illustrate that the prohibitions 
found in the CSA and the Gonzales court admonition were undoubtedly meant to apply to 
the distribution of controlled substances via the internet by online pharmacies.216 Case law 
contains numerous examples of defendants charged with violations of the CSA prior to the 
passage of the Ryan Haight Act. Under the Ryan Haight Act, the scope of the CSA was 
broadened to include regulations regarding the practice of telemedicine and the use of the 
internet in the distribution of controlled substances.217
In United States v. Darji and United States v. Hazelwood, the defendants were 
charged with violations of the CSA218 related to their operation of an illicit online 
 209. Id. § 882(c)(2). 
 210. S. Rep. No. 110-521, at 1 (2008). 
 211. Id. at 2. 
 212. Id. at 9. 
 213. Id. at 7; see also State v. Sowell, 213 N.J. 89, 105 (N.J. 2013) (“Nearly all criminal activity involves some 
effort at concealment.”). 
 214. S. Rep. No. 110-521, at 4 (2008); see also Digital Pharmacy Accreditation, NABP, 
https://nabp.pharmacy/programs/vipps/ (last visited Jan. 24, 2021). This program was started as a way for 
consumers to verify the legitimacy of an online pharmacy. If a consumer is looking to make illegitimate drug 
purchases online, this voluntary program seems wholly ineffective. 
 215. 546 U.S. 243, 269–70 (2006). 
 216. Cases explored infra.
 217. S. Rep. No. 110-521, at 12–13 (2008). 
 218. United States v. Darji, 609 Fed. App’x. 320, 323 (6th Cir. 2015); United States v. Hazelwood, 2011 WL 
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pharmacy.219 This case highlights the difference between the in-person encounter 
requirement220 found in the Ryan Haight Act and the “legitimate medical purpose” 
language found in the Controlled Substances Act. The defendants were indicted prior to 
the passage of the Ryan Haight Act on charges involving an internet pharmacy distributing 
controlled substances based on a submitted questionnaire. Since the CSA contains 
language that prohibits the distribution of controlled substances outside the normal scope 
of professional practice, internet “pill mill”221 pharmacy operators were routinely charged 
and convicted prior to the passage of the Ryan Haight Act.  
The Darji defendants were charged, along with several others, with numerous 
offenses based on their involvement in the illicit online pharmacy.222 The court 
characterized the operation as an “Internet-based drug trafficking organization”223 and an 
“internet pill mill.”224 Undercover agents were able to demonstrate the illegitimate nature 
of the medical review used to evaluate the online questionnaire responses. One agent 
submitted responses describing pain from “heartworms, and excessive barking” and listed 
current medications as Kyltix and Nylabone.225 He was prescribed hydrocodone on three 
separate occasions.226 Another agent was able to obtain hydrocodone using medical 
records “submitted by a pregnant man.”227
The defendants filed several motions to contest the charges against them.228 The 
defendants argued that the charges against them should be dismissed because their conduct 
was not a violation of the CSA at the time.229 The defendants relied on the in-person 
encounter requirement created by the Ryan Haight Act to argue that their actions were not 
per se illegal prior to the passage of the act.230 In response to that argument, the court 
2565294. (Both cases stem from the same underlying facts.) 
 219. Internet pharmacies are generally grouped into one of three categories. First are those that fill 
prescriptions pursuant to a legitimate prescription. These are generally associated with a traditional brick and 
mortar pharmacy and largely exist to service existing customers. In the second category are pharmacies that 
provide prescriptions after a physician reviews an online questionnaire completed by a consumer. These 
pharmacies have an air of legitimacy because of their association with licensed physicians. In the third category 
are the rogue internet pharmacies not connected to any licensed physician or pharmacist and that sell drugs 
directly to consumers. The focus of the Ryan Haight Act was on category two pharmacies. For a complete 
discussion on the different categories of online pharmacies, see Bethany Lipman, Note, Prescribing Medicine 
for Online Pharmacies: An Assessment of the Law and a Proposal to Combat Illegal Drug Outlets, 50 AM. L.
REV. 545, 549 (2013); see also Ludmila Bussiki Silva Clifton, Comment, Internet Drug Sales: Is It Time to 
Welcome “Big Brother” into Your Medicine Cabinet?, 20 J. CONTEMP. HEALTH L. & POL’Y 541, 546 (2004). 
 220. 21 U.S.C. § 829(e)(2)(A). 
 221. United States v. Hazelwood, Case No.: 1:10 CR 150, 2011 WL 2565294, at *23–24 (N.D. Ohio Nov. 22, 
2011). “Pill mill” is a slang term to refer to pharmacies that fill inordinate amounts of controlled substance 
prescriptions. The judge held in this case that the term was a “factually supported and proper” way to refer to the 
operations of the defendants. 
222. Hazelwood, 2011 WL 2565294, at *1. 
 223. Id. at *1. 
 224. Id. at *2. 
225. Darji, 609 F. App’x. at 324. 
226. Id. 
227. Id. 
228. Hazelwood, 2011 WL 2565294, at *1. 
 229. Id. at *3. 
 230. Id. at *3. 
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conducted a thorough examination of the CSA and the Ryan Haight Act. 231
The court noted that the CSA provides that “it shall be unlawful for any person 
knowingly or intentionally - (1) to manufacture, distribute, or dispense a controlled 
substance.”232 An exception to this broad prohibition is provided for the practice of 
medicine. A controlled substance may be dispensed or prescribed “for a legitimate medical 
purpose by an individual practitioner acting the usual course of his professional 
practice.”233
There are no statutory definitions of legitimate medical purpose and the CSA “does 
not specifically define the range of acceptable medical practices.”234 In several online 
pharmacy cases, defendants argued that the CSA was unconstitutionally vague because of 
the lack of definition for legitimate medical purpose.235 In United States v. Orta-Rosario,
the 4th Circuit rejected a claim that the CSA was impermissibly vague.236 The Orta-
Rosario court concluded that since “there are no specific guidelines concerning what is . . . 
outside the usual course of professional practice,” courts “must engage in a case-by-case 
analysis” to determine if defendants have violated the CSA.237 Courts have generally held 
that “[t]he term professional practice refers to generally accepted medical practice.”238
The Darji court contrasted the language of the CSA with that found in the Ryan 
Haight Act. The Ryan Haight Act narrows the exception available for dispensing 
controlled substances by prescription. The Act created the requirement of a valid 
prescription, which requires the practitioner to conduct at least one in-person medical 
evaluation of the patient. This language is in addition to the “legitimate medical purpose” 
requirement.  
The Government conceded that the Ryan Haight Act was not applicable to the Darji
defendants but maintained that their conduct was a violation of the CSA. The defendants 
were being charged for distributing controlled substances “outside the usual scope of 
professional practice.”239 The fact that their activity involved the internet was 
irrelevant.240
The Birbragher case demonstrates the wide array of statutory penalties possible for 
violations of the CSA by an individual who is not a physician or pharmacy.241 The 
defendant was involved in an elaborate plan to distribute controlled substances via the 
internet. The defendant operated Pharmacom, a company that “used the internet to 
231. Hazelwood, 2011 WL 2565294. 
 232. Id. at *3; 21 U.S.C. § 841(a)(1). 
 233. 21 C.F.R §1306.04(a). 
 234. United States v. Orta-Rosario, 469 F. App’x 140, 143 (2012).
235. See United States v. Birbragher, 603 F.3d 478 (8th Cir. 2010); United States v. Lovern, 590 F.3d 1095, 
1103 (10th Cir. 2009); United States v. Quinones, 536 F. Supp. 2d 267, 273 (E.D.N.Y. 2008). 
 236. 469 F. App’x. 140, 143. 
237. Id. (quoting United States v. Singh, 54 F.3d 1182, 1187 (4th Cir. 1995)). 
 238. United States v. Vamos, 797 F.2d 1146, 1151 (2d Cir. 1986) (internal quotations omitted). 
 239. Hazelwood, 2011 WL 2565294, at *4.
240. See Quinones, 536 F. Supp. 2d at 271 (finding the fact that the defendants allegedly carried out their 
activities through the internet to be irrelevant to the charges). 
 241. See Birbragher, 603 F.3d 478 (8th Cir. 2010); see also 21 U.S.C. § 822(a)–(b) (The distinction between 
individual physicians and a pharmacy as an entity is found in the statute. The DEA registers individual prescribers 
and pharmacies, as opposed to individual pharmacists.).  
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distribute prescription drugs.”242 Pharmacom operated the typical website where patients 
filled out a questionnaire that would be submitted to a physician. However, Pharmacom 
did not operate a pharmacy but rather contracted with one to dispense the “approved 
‘prescription’ orders.”243 During the course of its operation, from January 2003 to May 
2004, Pharmacom spent $3.14 million on internet advertising and marketing.244
Physicians were employed from around the country. Some were not even licensed to 
practice medicine in the U.S.245
In a 2007 indictment, Birbragher and his codefendants were charged with multiple 
drug and money laundering violations.246 Birbragher was charged with conspiracy to 
violate provisions of the CSA related to dispensing controlled substances outside the usual 
course of professional practice.247 He was also charged with leasing space to maintain a 
pharmacy “for the purpose of distributing Schedule III and Schedule IV controlled 
substances” outside the usual course of practice.248 Further, he was charged with 
conspiring to violate 21 U.S.C. § 861(a)(1) for “knowingly and intentionally employ[ing] 
minors, to violate the drug laws.”249
In addition to the drug related charges, Birbragher was indicted for conspiring to 
“conduct . . . financial transactions involving the proceeds of the . . . drug conspiracy.”250
Each of the conspiracy charges related back to the “unlawful activity” of the “illegal 
dispensing of Schedule III and IV controlled substances.”251
Similar to other online pharmacy defendants, Birbragher asserted in his defense that 
the CSA was unconstitutionally vague in violation of the Fifth Amendment right to due 
process.252 However, unlike the Darji defendants, Birbragher argued that the CSA was 
vague as applied to himself as a non-physician or non-pharmacist. The court noted that 21 
U.S.C. § 841(a)(1) bars “any person [from] knowingly or intentionally . . . 
manufactur[ing], distribut[ing], or dispens[ing] . . . a controlled substance.”253 The 
exception for medical practice, rather than the general bar, unsurprisingly applies to 
physicians and pharmacies acting in the usual course of professional practice. 
B. Ineffective Legislation—The Ryan Haight Act Has Failed to Curtail Illicit Online 
Pharmacies 
The cases listed supra illustrate the types of activity—the illicit distribution of large 
amounts of controlled substances, clearly outside the bounds of professional medical 
practice—that the Ryan Haight Act sought to prohibit. However, as demonstrated by the 
242. Birbragher, 603 F.3d at 481. 
243. Id. (internal quotations omitted). 
244. Id. at 482. 
245. Id. at 481 
246. Id. at 482. 
247. Birbragher, 603 F.3d at 482. 
248. Id. at 483. 
249. Id. at 482. 
250. Id. at 483. 
251. Id.
252. Birbragher, 603 F.3d at 484. 
253. Id. at 486; see also 21 U.S.C. § 841(a)(1). 
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cases, statutory and regulatory tools to combat this type of behavior existed prior to the 
passage of the Act. These “pill mill” cases did not involve a valid patient-prescriber 
relationship, nor was one contemplated. These operations were clearly outside the bounds 
of professional conduct and were designed to distribute as many controlled substances 
prescriptions as possible to maximize profits.  
The legislative history of the Ryan Haight Act reveals that some of the underlying 
justifications of the act were fundamentally flawed. Joseph Rannazzisi, then a deputy 
assistant administrator at the DEA, testified that the “DEA believes a majority of the rogue 
[pharmacy] sites operating today are based in the United States . . . .”254 However, a 2016 
report estimated 30,000 to 35,000 illicit online pharmacies were in operation, with most 
located outside of the U.S.255
Mr. Rannazzisi also testified to the effect that the DEA thought the online 
questionnaire format was “in many cases . . . a ruse created to identify exactly what type 
of prescription controlled substance the customer wants to purchase.”256 The remedy to 
this was to define a valid prescription as requiring at least one face-to-face meeting. 
However, a 2008 study from the National Center on Addiction and Substance Abuse 
(CASA) estimated that “nearly 85% of Web sites offering controlled prescription 
medications for sale do not require a legitimate prescription.”257
Another issue is the narrow definition of telemedicine found in the CSA. Congress 
should amend the CSA to include the commonly accepted and practiced definition of 
telemedicine. This would yield a more effective and patient-centered approach to treatment 
of OUD. Expanding the statutory definition of telemedicine to allow for interactions 
between a physician and a patient who is at home would dramatically increase the access 
to clinically effective substance abuse treatment.  
The statutory definitions of telemedicine are far too restrictive and simply fail to 
accommodate the current practice of telemedicine.258 Telemedicine is broken down into 
seven subtypes. One subtype includes a situation where the patient is being treated by a 
remote physician while in the physical presence of another physician. While this definition 
would be useful in connecting a patient with a distantly located specialist, such as a 
consultation with a gastroenterologist, it does not account for the current realities of health 
care. This definition requires the presence of two licensed physicians. Given the current 
physician shortage,259 it is unlikely that a patient would timely be able to arrange such an 
appointment. 
In November 2018, the Indian Health Service (“IHS”) announced a new policy to 
 254. Rogue Online Pharmacies: The Growing Problem of Internet Drug Trafficking: Hearing Before the S. 
Comm. on the Judiciary, 110th Cong. (2007) (written statement of Joseph T. Rannazzisi, Deputy Assistant 
Adm’r, Office of Diversion Control, U.S. Drug Enforcement Admin.). 
 255. Internet Pharmacies: Most Rogue Sites Operate from Abroad, and Many Sell Counterfeit Drugs: 
Testimony Before the H. Subcomm. on Oversight and Investigations, 113th Cong. (2014) (statement of Marcia 
Crosse, Director, Health Care, U.S. Government Accountability Office). 
 256. S. Rep. No. 110-521, at 10 (2008). 
 257. Anupam B. Jena, et al., Prescription Medication Abuse and Illegitimate Internet-Based Pharmacies, 155 
ANN. INTERN. MED. 848 (2011). 
 258. 21 U.S.C. § 802(54)(E). 
 259. New Findings Confirm Predictions on Physician Shortage, AM. ASS’N. MED. COL. (Apr. 23, 2019), 
https://www.aamc.org/news-insights/press-releases/new-findings-confirm-predictions-physician-shortage. 
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expand access to MAT in remote locations.260 One of the definitions of telemedicine 
includes certain providers who are employed by IHS.261 This definition dispenses with the 
need for a licensed practitioner to be physically located with the patient. Acknowledging 
the difficulty of accessing care in rural or remote areas, combined with the limited number 
of DATA 2000-waived providers, IHS said that the new policy will allow patients to 
access care more conveniently while reducing the time to start treatment.262 This 
potentially lowers the risk of relapse and overdose death.263
Included in the CSA’s list of exceptions to the in-person examination requirement is 
the Special Registration Process.264 This exception waives the in-person exam 
requirement for practitioners specially registered with the DEA. To date, the procedure for 
applying for the special registration has not been announced. In late 2019, the DEA 
announced a proposed rule that would activate the special registration exception and 
establish the situations where special registration would apply. While this would increase 
the number of substance abuse treatment providers available, especially in rural areas, it 
still serves as an unnecessary limit on access to treatment.  
For these reasons Congress should remove the in-person medical examination 
requirement from the CSA or update the definition of telemedicine to include the reality 
of current medical practice. Increasing access, through another exception that requires 
practitioners to meet several requirements, is not a solution. While the original intentions 
of the Ryan Haight Act were noble, the unintended consequences of the in-person exam 
requirement work in opposition to the goal of the act. With advances in high-speed internet 
and high-definition video, a practitioner can conduct a thorough medical encounter 
without the necessity of an in-person visit. 
C. Symptoms of Overregulation—U.S. Drug Policy Adds Regulations to Solve Problems 
Caused by Regulations 
Iatrogenic illness is a disease state or symptom caused by a medical treatment. A 
typical situation involves prescribing an additional medicine to treat the side effects of the 
first medicine. This presents a striking analogy to the restrictions placed on MAT-therapy 
for OUD. Controlled substance regulations, designed to control access to dangerous, 
addictive drugs, also makes it more difficult to obtain treatment for addiction to dangerous, 
addictive drugs.  
One theme that is readily apparent in U.S. drug policy is the reliance on regulations 
to solve problems caused by regulations. In 1919, the U.S. Supreme Court held that the 
Harrison Narcotic Act prohibited the prescribing and dispensing of morphine to a habitual 
user in order to “keep him comfortable by maintaining his customary use.”265 This federal 
stance on addiction, and on medicine’s role in the treatment of addiction, would affect 
 260. IHS Announces a New Policy to Expand Access to Medication Assisted Treatment in Remote Locations,
IHS, https://www.ihs.gov/newsroom/ihs-blog/november2018/ihs-announces-a-new-policy-to-expand-access-to-
medication-assisted-treatment-in-remote-locations/ (last visited Jan. 24, 2021). 
 261. 21 U.S.C. § 802(54)(C). 
 262. See IHS, supra note 260. 
263. Id. 
 264. 21 U.S.C. § 831(h). 
 265. Webb v. United States, 249 U.S. 96, 99 (1919). 
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addiction treatment for fifty-six years until the passage of the CSA.  
The CSA, as amended by NATA 1974, allowed physicians to dispense medications 
for maintenance and detoxification treatment. Finally, individuals with OUD could seek 
medical intervention for their condition. However, the restrictions imposed upon addiction 
treatment, such as stringent controls on the amount of medicine a physician could give a 
patient, created the typical “methadone clinic”266 experience. Patients were required to 
make daily trips to the clinic to receive daily doses because Congress feared that patients 
would abuse methadone if given more than a few pills at a time. 
With DATA 2000, Congress expanded access to MAT by allowing physicians to 
treat OUD in an office-based setting like any other chronic condition. A patient was able 
to see a physician in the privacy of a clinic office. Prescriptions for medication, typically 
buprenorphine, could be written and filled at the patient’s local pharmacy. With a month 
supply of medication, the patient can focus on recovery rather than planning for another 
trip to the methadone clinic.  
However, with the increase came another set of regulations. To obtain a DATA 2000 
waiver, a physician is required to meet one of several onerous requirements. A physician 
must have a board certification in addiction medicine, complete additional training in 
addiction medicine, or have participated as an investigator in a clinical trial that lead “to 
the approval of a narcotic drug in Schedule III, IV, or V for maintenance or detoxification 
treatment.”267 After meeting one of these requirements, a physician is then limited to the 
number of patients she may treat. While the ability to prescribe buprenorphine in this 
setting has been expanded to include nurse practitioners and physician assistants, the 
unnecessary barriers of additional registration still prevent access to treatment by those 
most in need.  
DATA 2000 also fails to recognize the safety and success of widespread access to 
buprenorphine treatment. Several addiction medicine organizations and physician groups 
have called on Congress to remove the restrictions on prescribing buprenorphine for OUD 
treatment. Proponents cite buprenorphine’s partial agonist status and its relative safety 
compared to commonly prescribed and less regulated full agonists such as oxycodone.268
The scope of the limitation created by the intersection of DATA 2000 and Ryan Haight 
Act restrictions becomes clearer when numbers are added to the analysis. Just 464 deaths 
related to buprenorphine were reported between 2002 and 2013, compared to the half a 
million overdose deaths between 2000 and 2014 involving mostly full opioid agonists, like 
oxycodone, fentanyl, or heroin.269
Another common reaction to the increase in opioid misuse and overdose deaths is to 
introduce or strengthen regulations for state-level prescription monitoring programs.270
 266. Methadone is a Schedule II opioid medication. It is used for both pain management and addiction 
treatment. Since it is in Schedule II, it is considered to have a high abuse potential and high likelihood of physical 
dependence if abused. This view lead to tight restrictions on its use, especially when treating OUD. 
 267. 21 U.S.C. § 823(g)(2)(G)(ii) 
 268. Kevin Fiscella, Buprenorphine Deregulation and Mainstreaming Treatment for Opioid Use Disorder, 76 
JAMA PSYCHIATRY 229 (2019). 
269. Id.
 270. Prescription Monitoring Programs (PMPs) are state-run databases for collecting information on the 
dispensing of controlled substance prescription medications. Dispensers, such as pharmacies or prescribers, are 
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However, while some evidence suggests that this leads to decreases in prescription drug 
misuse, a concomitant rise in heroin use occurs.271 Other studies have found that when 
regulations increase the restrictions on Schedule II medications, physicians shift to less-
regulated Schedule III medications instead of decreasing overall opioid prescribing.272
Congress should adopt a policy of decreasing regulations in order to increase access 
to treatment for OUD. All of these instances and situations listed above indicate that more 
regulations do not provide meaningful reductions in opioid abuse and misuse. Rather than 
continuing to focus on approaches that limit access to opioids, both licit and illicit, 
Congress should take steps to increase access to treatment for OUD. Removing the 
restrictions on prescribing buprenorphine in an office-based setting would be a productive 
step toward decreasing opioid abuse and misuse. 
V. CONCLUSION
Due to the unique pharmacology of opioids and pathophysiology of OUD, increased 
and improved access to treatment and experienced practitioners is necessary. Efforts by 
IHS and VHA to increase access to MAT using telemedicine have proven effective. In the 
time it takes to read this comment, five people will have died from an opioid overdose. 
Press conferences announcing good intentions followed by inaction have cost thousands 
of lives. Half-steps to improve access continue to take time that would more effectively be 
used to treat patients with OUD.  
Given the disparate impact of the opioid epidemic on rural areas, combined with the 
lack of access to mental health professionals and addiction specialists, legislative and 
regulatory action to improve and expand access to telemedicine services is needed. Access 
to treatment for OUD from the privacy and convenience of your home would dramatically 
increase the number of patients that receive this effective therapy.  
The combined effect of the DATA 2000 and Ryan Haight Act amendments to the 
CSA work to artificially and unnecessarily limit the number and availability of substance 
use treatment providers. Congress has shown the ability to focus on the problem of the 
opioid epidemic, but not the willingness to make substantial changes. Increasing access to 
treatment, rather than limiting access to opioids, will have a greater impact on patients 
with OUD and should be the approach adopted by Congress.273
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required to report to the database information such as the patient name, drug name and strength, and quantity. 
The information is then available for other healthcare providers to review prior to prescribing or dispensing a 
controlled substance prescription. See Anca M. Grecu, Mandatory Access Prescription Drug Monitoring 
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 271. Grecu, supra note 270, at 181. 
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Combination Products Claims in a Medicaid Population, 23 J. MANAG. CARE SPEC. PHARM. 532, 533 (2017). 
* Joshua D. McCann is a JD/MBA candidate at the University of Tulsa College of Law. During his time in law 
school, the author served as Executive IT Editor of Tulsa Law Review and Treasurer of OUTLaws. Prior to 
attending law school, Dr. McCann worked as a pharmacist in a variety of healthcare settings. After graduation, 
he plans to concentrate on transactional and regulatory law in the healthcare sector. The author would like to 
thank his family for their patience, love, and encouragement throughout law school. 
273
26
Tulsa Law Review, Vol. 56 [2020], Iss. 2, Art. 8
https://digitalcommons.law.utulsa.edu/tlr/vol56/iss2/8
